Determinants of inhibitor development in previously treated hemophilia A patients

被引：0

作者：

Iorio, A. ^{[1
,2
]}

Barbara, A. ^{[3
]}

Castaman, G. ^{[4
]}

Fischer, K. ^{[5
]}

Gilman, E. ^{[6
]}

Goudemand, J. ^{[7
]}

Kavakli, K. ^{[8
]}

Kubicek-Hofmann, C. ^{[9
]}

Lambert, T. ^{[10
]}

Lissitchkov, T.

Makris, M. ^{[6
]}

Matthew, P. ^{[11
]}

Castelano, M. E. M.

Ozdemir, N.

Parra, R.

Peerlinck, K.

Rivolta, G. ^{[12
]}

Romanov, V ^{[13
]}

Roussel-Robert, V

Tagliaferri, A. ^{[14
]}

Windyga, J. ^{[15
]}

Zanon, E. ^{[16
]}

机构：

[1] McMaster Univ, Dept Clin Epidemiol, Hamilton, ON L8S 4L8, Canada

[2] McMaster Univ, Med, Hamilton, ON, Canada

[3] McMaster Univ, Clin Epidemiol & Biostat, Hamilton, ON, Canada

[4] Azienda Osped Policlin Careggi, Florence, Italy

[5] Van Creveld Clin, Utrecth, Netherlands

[6] Univ Sheffield, Sheffield, S Yorkshire, England

[7] Univ Lille, Lille, France

[8] Unviers Izmir, Izmir, Turkey

[9] Univ Berlin, Berlin, Germany

[10] Univ Paris, F-75252 Paris, France

[11] Bayer, Pittsburgh, PA USA

[12] Policlin Univ, Parma, Italy

[13] Baxter Healthcare, Los Angeles, CA USA

[14] Policlin Univ, Parma, Italy

[15] Univ Warsaw, Warsaw, Poland

[16] Univ Padua Polyclin, Padua, Italy

来源：

JOURNAL OF THROMBOSIS AND HAEMOSTASIS | 2015年 / 13卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

OR144

引用

下载

页码：149 / 149

页数：1

共 50 条

[21] Timing of inhibitor development in more than 1000 previously untreated patients with severe hemophilia A
van den Berg, H. Marijke
Fischer, Kathelijn
Carcao, Manuel
Chambost, Herve
Kenet, Gili
Kurnik, Karin
Konigs, Chris
Male, Christoph
Santagostino, Elena
Ljung, Rolf
BLOOD, 2019, 134 (03) : 317 - 320
[22] Recombinant FVIII product type and the risk of inhibitor development in previously treated patients with hemophilia A: a systematic review and meta-analysis
Hassan, S.
Cannavo, A.
van der Bom, J.
Gouw, S.
Rosendaal, F.
HAEMOPHILIA, 2018, 24 : 124 - 125
[23] Validation of the prediction score for inhibitor development in previously untreated patients (PUPs) with severe hemophilia A
Hashemi, S.
Fischer, K.
Van den Berg, H.
HAEMOPHILIA, 2012, 18 : 89 - 89
[24] Exploration of biomarkers for early recognition of FVIII inhibitor development in previously untreated severe hemophilia A patients: Hemophilia Inhibitor PUP Study and beyond
Hofbauer, C. J.
Male, C.
Brown, D.
Santagostino, E.
Oldenburg, J.
Scheiflinger, F.
Reipert, B. M.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 : 133 - 133
[25] Risk of Bleeding and Inhibitor Development After Circumcision of Previously Untreated or Minimally Treated Severe Hemophilia A Children
Elalfy, Mohsen S.
Elbarbary, Nancy S.
Eldebeiky, Mohamed S.
El Danasoury, Azza S.
PEDIATRIC HEMATOLOGY AND ONCOLOGY, 2012, 29 (05) : 485 - 493
[26] Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review
Iorio, A.
Halimeh, S.
Holzhauer, S.
Goldenberg, N.
Marchesini, E.
Marcucci, M.
Young, G.
Bidlingmaier, C.
Brandao, L. R.
Ettingshausen, C. E.
Gringeri, A.
Kenet, G.
Knoefler, R.
Kreuz, W.
Kurnik, K.
Manner, D.
Santagostino, E.
Mannucci, P. M.
Nowak-Goettl, U.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2010, 8 (06) : 1256 - 1265
[27] Factor VIII prophylaxis and inhibitor development in previously untreated patients with severe hemophilia A: the RODIN study
Gouw, S. C.
Van den Berg, M.
Auerswald, G.
Carcao, M.
Chalmers, E.
Chambost, H.
Fischer, K.
Kurnik, K.
Liesner, R.
Petrini, P.
Platokouki, H.
Altisent, C.
Oldenburg, J.
Nolan, B.
Perez Garido, R.
Rafowicz, A.
Williams, M.
Van der Bom, J. G.
HAEMOPHILIA, 2012, 18 : 3 - 4
[28] Inhibitor development, safety, and efficacy of Advate® in previously untreated patients with hemophilia A in a postmarketing surveillance in Japan
Masashi Taki
Katsuyuki Fukutake
Tadashi Matsushita
Keiji Nogami
Midori Shima
Akira Yoshioka
Junki Takamatsu
Morio Arai
Hiroshi Takagi
Haruhiko Uchikawa
Werner Engl
Akira Shirahata
International Journal of Hematology, 2019, 109 : 70 - 78
[29] Inhibitor development, safety, and efficacy of Advate® in previously untreated patients with hemophilia A in a postmarketing surveillance in Japan
Taki, Masashi
Fukutake, Katsuyuki
Matsushita, Tadashi
Nogami, Keiji
Shima, Midori
Yoshioka, Akira
Takamatsu, Junki
Arai, Morio
Takagi, Hiroshi
Uchikawa, Haruhiko
Engl, Werner
Shirahata, Akira
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2019, 109 (01) : 70 - 78
[30] EFFECT OF DNA METHYLATION ON INHIBITOR DEVELOPMENT IN HEMOPHILIA A PATIENTS TREATED WITH FVIII CONCENTRATES
Chand, H.
Hassan, S.
Cairo, A.
Palla, R.
Peyvandi, F.
HAEMOPHILIA, 2023, 29 : 27 - 27

← 1 2 3 4 5 →